SPDR S&P Biotech ETF (NYSEARCA:XBI – Get Free Report) shares reached a new 52-week high on Monday . The company traded as high as $161.20 and last traded at $159.98, with a volume of 882429 shares trading hands. The stock had previously closed at $160.46.
SPDR S&P Biotech ETF Stock Up 1.9%
The firm has a market capitalization of $11.16 billion, a price-to-earnings ratio of 11.47 and a beta of 0.82. The company has a 50-day moving average price of $138.55 and a 200-day moving average price of $130.59.
Institutional Investors Weigh In On SPDR S&P Biotech ETF
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Axiom Investment Management LLC acquired a new position in SPDR S&P Biotech ETF during the 1st quarter valued at about $26,000. Financial Life Planners acquired a new stake in shares of SPDR S&P Biotech ETF in the 1st quarter worth approximately $27,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of SPDR S&P Biotech ETF in the fourth quarter valued at approximately $27,000. Intesa Sanpaolo Wealth Management bought a new position in shares of SPDR S&P Biotech ETF in the fourth quarter valued at approximately $30,000. Finally, SHP Wealth Management acquired a new position in shares of SPDR S&P Biotech ETF during the fourth quarter valued at approximately $31,000.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
Featured Articles
- Five stocks we like better than SPDR S&P Biotech ETF
- Apple and Broadcom Forge a Decade-Long Silicon Fortress
- SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
- The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity
- Palantir’s CEO Just Called Out OpenAI and Anthropic
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
